

By: Representative Hobgood-Wilkes

To: Drug Policy; Business
and Commerce

HOUSE BILL NO. 1121

1 AN ACT TO AMEND SECTION 41-29-117, MISSISSIPPI CODE OF 1972,
2 TO ADD KRATOM TO SCHEDULE III OF THE UNIFORM CONTROLLED SUBSTANCES
3 ACT; AND FOR RELATED PURPOSES.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

5 **SECTION 1.** Section 41-29-117, Mississippi Code of 1972, is
6 amended as follows:

7 41-29-117. (A) The controlled substances listed in this
8 section are included in Schedule III.

9 **SCHEDULE III**

10 (a) **Stimulants.** Any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 substances or their salts, isomers, or salts of isomers, of the
13 following substances:

- 14 (1) Benzphetamine;
15 (2) Chlorphentermine;
16 (3) Clortermine;
17 (4) Phendimetrazine.

18 (b) **Depressants.** Unless listed in another schedule,
19 any material, compound, mixture, or preparation which contains any
20 quantity of the following substances:

21 (1) Any substance which contains any quantity of a
22 derivative of barbituric acid, or any salt of a derivative of
23 barbituric acid, except those substances which are specifically
24 listed in other schedules;

25 (2) Unless specifically excepted or unless listed
26 in another schedule, any compound, mixture or preparation
27 containing any of the following substances or any salt of the
28 substances specifically included in this subsection (2) and one or
29 more other active medicinal ingredients which are not listed in
30 any other schedule:

31 (i) Amobarbital;

32 (ii) Secobarbital;

33 (iii) Pentobarbital;

34 (3) Any suppository dosage form containing any of
35 the following substances or any salt of any of the substances
36 specifically included in this subsection (3) approved by the Food
37 and Drug Administration for marketing only as a suppository:

38 (i) Amobarbital;

39 (ii) Secobarbital;

40 (iii) Pentobarbital;

41 (4) Chlorhexadol;

42 (5) Embutramide;

43 (6) Any drug product containing
44 gamma-hydroxybutyric acid, including its salts, isomers and salts
45 of isomers, for which an application is approved under Section 505
46 of the Federal Food, Drug and Cosmetic Act;

47 (7) Ketamine; its salts, isomers, and salts of
48 isomers; other names include
49 (+)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone;

50 (8) Lysergic acid;

51 (9) Lysergic acid amide;

52 (10) Methyprylon;

53 (11) Perampanel; its salts, isomers, and salts of
54 isomers;

55 (12) Sulfondiethylmethane;

56 (13) Sulfonethylmethane;

57 (14) Sulfonmethane;

58 (15) Tiletamine and zolazepam or any salt thereof;

59 other names for the tiletamine and zolazepam combination product
60 include: telazol; other names for tiletamine include:

61 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; other names for

62 zolazepam include: 4-(2-fluorophenyl)-6,8-dihydro 1,3,

63 8-trimethylpyrazolo-[3,4-e](1,4)-diazepin-7(1H)-one, flupyrazapon.

64 (c) Nalorphine.

65 (d) Any material, compound, mixture or preparation
66 which contains any quantity of ephedrine or pseudoephedrine,
67 except for any product that contains any quantity of

68 pseudoephedrine or ephedrine that is sold subject to the quantity
69 restrictions authorized in Section 73-21-124.

70 (e) **Narcotic drugs.** Any material, compound, mixture,
71 or preparation containing limited quantities of any of the
72 following narcotic drugs, or any salts thereof:

73 (1) Not more than one and eight-tenths (1.8) grams
74 of codeine, or any of its salts, per one hundred (100) milliliters
75 or not more than ninety (90) milligrams per dosage unit, with an
76 equal or greater quantity of an isoquinoline alkaloid of opium;

77 (2) Not more than one and eight-tenths (1.8) grams
78 of codeine, or any of its salts, per one hundred (100) milliliters
79 or not more than ninety (90) milligrams per dosage unit, with one
80 or more active, nonnarcotic ingredients in recognized therapeutic
81 amounts;

82 (3) Not more than one and eight-tenths (1.8) grams
83 of dihydrocodeine, or any of its salts, per one hundred (100)
84 milliliters or not more than ninety (90) milligrams per dosage
85 unit, with one or more active, nonnarcotic ingredients in
86 recognized therapeutic amounts;

87 (4) Not more than three hundred (300) milligrams
88 of ethylmorphine, or any of its salts, per one hundred (100)
89 milliliters or not more than fifteen (15) milligrams per dosage
90 unit, with one or more active, nonnarcotic ingredients in
91 recognized therapeutic amounts;

92 (5) Not more than five hundred (500) milligrams of
93 opium per one hundred (100) milliliters or per one hundred (100)
94 grams, or not more than twenty-five (25) milligrams per dosage
95 unit, with one or more active, nonnarcotic ingredients in
96 recognized therapeutic amounts;

97 (6) Not more than fifty (50) milligrams of
98 morphine, or any of its salts, per one hundred (100) milliliters
99 or per one hundred (100) grams with one or more active,
100 nonnarcotic ingredients in recognized therapeutic amounts.

101 (f) **Anabolic steroids.** Unless specifically exempted or
102 listed in another schedule, any material, compound, mixture or
103 preparation containing any quantity of any of the following
104 anabolic steroids (any drug or hormonal substance chemically and
105 pharmacologically related to testosterone other than estrogens,
106 progestins, corticosteroids and dehydroepiandrosterone):

107 (1) 3beta,17-dihydroxy-5a-androstane;

108 (2) 3alpha,17beta-dihydroxy-5a-androstane;

109 (3) 5alpha-androstan-3,17-dione;

110 (4) 1-androstenediol
111 (3beta,17beta-dihydroxy-5alpha-androst-1-ene);

112 (5) 1-androstenediol
113 (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);

114 (6) 4-androstenediol
115 (3beta,17beta-dihydroxy-androst-4-ene);

116 (7) 5-androstenediol
117 (3beta,17beta-dihydroxy-androst-5-ene);
118 (8) 1-androstenedione ([5alpha]-androst-1-en-3,
119 17-dione);
120 (9) 4-androstenedione (androst-4-en-3,17-dione);
121 (10) 5-androstenedione (androst-5-en-3,17-dione);
122 (11) Bolasterone
123 (7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
124 (12) Boldenone
125 (17beta-hydroxyandrost-1,4,-diene-3-one);
126 (13) Boldione (androsta-1,4-diene-3,17-dione);
127 (14) Calusterone
128 (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
129 (15) Clostebol
130 (4-chloro-17beta-hydroxyandrost-4-en-3-one);
131 (16) Dehydrochloromethyltestosterone
132 (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4-dien-3-one);
133 (17) Desoxymethyltestosterone
134 (17alpha-methyl-5alpha-androst-2-en-17beta-ol, also known as
135 madol);
136 (18) Delta1-dihydrotestosterone (also known as
137 1-testosterone) (17beta-hydroxy-5alpha-androst-1-en-3-one);
138 (19) 4-dihydrotestosterone
139 (17beta-hydroxy-androstan-3-one);

140 (20) Drostanolone
141 (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);
142 (21) Ethylestrenol
143 (17alpha-ethyl-17beta-hydroxyestr-4-ene);
144 (22) Fluoxymesterone
145 (9-fluoro-17alpha-methyl-11beta,
146 17beta-dihydroxyandrost-4-en-3-one);
147 (23) Formebolone
148 (2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,
149 4-dien-3-one);
150 (24) Furazabol
151 (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);
152 (25) 13beta-ethyl-17alpha-hydroxygon-4-en-3-one;
153 (26) 4-hydroxytestosterone
154 (4,17beta-dihydroxyandrost-4-en-3-one);
155 (27) 4-hydroxy-19-nortestosterone
156 (4,17beta-dihydroxy-estr-4-en-3-one);
157 (28) Mestanolone
158 (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);
159 (29) Mesterolone
160 (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);
161 (30) Methandienone
162 (17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);
163 (31) Methandriol (17alpha-methyl-3beta,
164 17beta-dihydroxyandrost-5-ene);

165 (32) Methasterone (2[alpha],
166 17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one;
167 (33) Methenolone
168 (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);
169 (34) 17alpha-methyl-3beta,
170 17beta-dihydroxy-5a-androstane;
171 (35) 17alpha-methyl-3alpha,
172 17beta-dihydroxy-5a-androstane;
173 (36) 17alpha-methyl-3beta,
174 17beta-dihydroxyandrost-4-ene;
175 (37) 17alpha-methyl-4-hydroxynandrolone
176 (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);
177 (38) Methyldienolone
178 (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);
179 (39) Methyltrienolone
180 (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);
181 (40) Methyltestosterone
182 (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);
183 (41) Mibolerone
184 (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);
185 (42) 17alpha-methyl-Delta1-dihydrotestosterone (17b
186 beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) (also known
187 as 17-alpha-methyl-1-testosterone);
188 (43) Nandrolone (17beta-hydroxyestr-4-en-3-one);

189 (44) 19-nor-4-androstenediol
190 (3beta,17beta-dihydroxyestr-4-ene);
191 (45) 19-nor-4-androstenediol
192 (3a,17beta-dihydroxyestr-4-ene);
193 (46) 19-nor-5-androstenediol
194 (3beta,17beta-dihydroxyestr-5-ene);
195 (47) 19-nor-5-androstenediol
196 (3alpha,17beta-dihydroxyestr-5-ene);
197 (48) 19-nor-4,9(10)-androstadienedione
198 (estra-4,9(10)-diene-3,17-dione,
199 19-norandrost-4,9(10)-diene-3,17-dione);
200 (49) 19-nor-4-androstenedione
201 (estr-4-en-3,17-dione);
202 (50) 19-nor-5-androstenedione
203 (estr-5-en-3,17-dione);
204 (51) Norbolethone
205 (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);
206 (52) Norclostebol
207 (4-chloro-17beta-hydroxyestr-4-en-3-one);
208 (53) Norethandrolone
209 (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);
210 (54) Normethandrolone
211 (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);
212 (55) Oxandrolone
213 (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);

214 (56) Oxymesterone
215 (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);
216 (57) Oxymetholone
217 (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-
218 androstan-3-one);
219 (58) Prostanazol
220 (17[beta]-hydroxy-5[alpha]-androstan[3,2-c]pyrazole)
221 (59) Stanozolol
222 (17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-
223 pyrazole);
224 (60) Stenbolone
225 (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);
226 (61) Testolactone
227 (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
228 lactone);
229 (62) Testosterone
230 (17beta-hydroxyandrost-4-en-3-one);
231 (63) Tetrahydrogestrinone
232 (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);
233 (64) Trenbolone
234 (17beta-hydroxyestr-4,9,11-trien-3-one);
235 (65) Any salt, ester, or ether of a drug or
236 substance described in this paragraph. Except such term does not
237 include an anabolic steroid that is expressly intended for
238 administration through implants to cattle or other nonhuman

239 species and that has been approved by the Secretary of Health and
240 Human Services for such administration. If any person prescribes,
241 dispenses, or distributes such steroid for human use, the person
242 shall be considered to have prescribed, dispensed or distributed
243 an anabolic steroid within the meaning of this paragraph.

244 (g) Any material, compound, mixture or preparation
245 which contains any quantity of buprenorphine or its salts.

246 (h) Dronabinol (synthetic) in sesame oil and
247 encapsulated in a soft gelatin capsule in a United States Food and
248 Drug Administration approved drug product.

249 (i) Any material, compound, mixture, or preparation
250 which contains any quantity of Tianeptine
251 (7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]th
252 iazepin-11-yl)amino)heptanoic acid) or its salts, isomers, salts
253 of isomers, sulfate, free acid or derivative thereof.

254 (j) Any material, compound, mixture or preparation that
255 contains any quantity of kratom (mitragynine and
256 7-hydroxymytragynine) or its salts, isomers, salts of isomers,
257 sulfate, free acid or derivative thereof.

258 (B) Any material, compound, mixture or preparation which
259 contains any quantity of a Schedule III controlled substance other
260 than butalbital, and is listed as an exempt substance in 21 CFR,
261 Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be
262 exempted from the provisions of the Uniform Controlled Substances
263 Law.

264 **SECTION 2.** This act shall take effect and be in force from
265 and after July 1, 2025.